High-Grade Glioma – Pipeline Review, H2 2019

Global Markets Direct’s, ‘High-Grade Glioma – Pipeline Review, H2 2019’, provides an overview of the High-Grade Glioma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma

– The report reviews pipeline therapeutics for High-Grade Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved High-Grade Glioma therapeutics and enlists all their major and minor projects

– The report assesses High-Grade Glioma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for High-Grade Glioma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aadi Bioscience Inc

Advanz Pharmaceutical Corp

Advenchen Laboratories LLC

AngioChem Inc

Apollomics Inc

Athenex Inc

Bayer AG

BeiGene Ltd

Berg LLC

Bio-Cancer Treatment International Ltd

Biomimetix JV LLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cellectar Biosciences Inc

Curis Inc

Curtana Pharmaceuticals Inc

DNAtrix Inc

Eisai Co Ltd

EpicentRx Inc

Erimos Pharmaceuticals LLC

Everfront Biotech Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genor BioPharma Co Ltd

GtreeBNT Co Ltd

Hanmi Pharmaceuticals Co Ltd

Ipsen SA

Karyopharm Therapeutics Inc

Mana Therapeutics Inc

Millennium Pharmaceuticals Inc

MimiVax LLC

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Oncoceutics Inc

Oncotelic Inc

Ono Pharmaceutical Co Ltd

Pfizer Inc

Prelude Therapeutics Inc

PTC Therapeutics Inc

Regeneron Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Targepeutics Inc

Tessa Therapeutics Pte Ltd

TheraBiologics Inc

TVAX Biomedical Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Introduction

High-Grade Glioma - Overview

High-Grade Glioma - Therapeutics Development

High-Grade Glioma - Therapeutics Assessment

High-Grade Glioma - Companies Involved in Therapeutics Development

High-Grade Glioma - Drug Profiles

High-Grade Glioma - Dormant Projects

High-Grade Glioma - Discontinued Products

High-Grade Glioma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for High-Grade Glioma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

High-Grade Glioma – Pipeline by Aadi Bioscience Inc, H2 2019

High-Grade Glioma – Pipeline by Advanz Pharmaceutical Corp, H2 2019

High-Grade Glioma – Pipeline by Advenchen Laboratories LLC, H2 2019

High-Grade Glioma – Pipeline by AngioChem Inc, H2 2019

High-Grade Glioma – Pipeline by Apollomics Inc, H2 2019

High-Grade Glioma – Pipeline by Athenex Inc, H2 2019

High-Grade Glioma – Pipeline by Bayer AG, H2 2019

High-Grade Glioma – Pipeline by BeiGene Ltd, H2 2019

High-Grade Glioma – Pipeline by Berg LLC, H2 2019

High-Grade Glioma – Pipeline by Bio-Cancer Treatment International Ltd, H2 2019

High-Grade Glioma – Pipeline by Biomimetix JV LLC, H2 2019

High-Grade Glioma – Pipeline by Boehringer Ingelheim International GmbH, H2 2019

High-Grade Glioma – Pipeline by Bristol-Myers Squibb Co, H2 2019

High-Grade Glioma – Pipeline by Cellectar Biosciences Inc, H2 2019

High-Grade Glioma – Pipeline by Curis Inc, H2 2019

High-Grade Glioma – Pipeline by Curtana Pharmaceuticals Inc, H2 2019

High-Grade Glioma – Pipeline by DNAtrix Inc, H2 2019

List of Figures

List of Figures

Number of Products under Development for High-Grade Glioma, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports